CA-C3.AI
8.12.2020 15:02:08 CET | Business Wire | Press release
C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today announced the winners of the C3.ai™ COVID-19 Grand Challenge . Launched on Sept. 15, the global competition encouraged developers, data scientists, students, and creative minds to build world-class data science techniques and strategies that accelerate novel COVID-19 research and drive smart and safe decision-making. The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic.
After a rigorous review process, the judging panel selected seven research projects for recognition. Judges assessed how well the entries leveraged data science techniques to derive insights that were not apparent before. The judges selected submissions that were most likely to unlock significant public health and economic benefits.
A total of $200,000 in cash prizes will be awarded to these research teams. Each has developed meaningful data-driven insights that will help the global community understand and mitigate not only the spread of COVID-19, but also prepare the world to fight future pandemics, improve the medical community’s ability to respond, and help policymakers navigate decisions about COVID-19.
C3.ai Grand Challenge Award Winners:
Grand Prize - $100,000
- Combined Diagnostics - Modeling Population Heterogeneity and Personalized COVID Diagnostics. Predicts an individual’s infectious and susceptibility status and probability of having COVID-19. The team applied the Bayesian Stochastic Expectation-Maximization method to demographics, individual health characteristics, and behavioral and geographical data to provide personalized estimates for each individual’s infectious and susceptibility statuses. (Freddy Bunbury - Carnegie Institution for Science, Nina Miolane - University of California, Santa Barbara, and Claire Donnat - University of Chicago)
“Any return to normality relies on accurately determining who might have COVID-19. Demographics, individual health characteristics, and behavioral and geographical data considerably alter one’s risk of catching, suffering from, and spreading the virus,” said Freddy Bunbury, post-doctoral researcher at the Carnegie Institution for Science. “Knowing this, we developed a machine learning model that is reactive, granular, and even personalized to help individuals, and – by extension – society, compute with greater accuracy the probability of having COVID-19. By intelligently combining these disparate data sources, we aim to more robustly capture people’s individual likelihood of having and spreading the disease, reduce false test results, and inform disease transmission models.”
“This project has huge potential to make an immediate impact on the pandemic with its approach to generating meaningful results from COVID testing,” said Thomas M. Siebel, CEO of C3.ai. “This is an unprecedented opportunity to apply informed decision-making based on data to enable daily life and business operations to continue, while effectively managing health risks.”
Second-Place Awards - $25,000 each
- DeepOutbreak: Framework for Forecasting Dynamics of COVID-19 and Co-Evolving Diseases . Models the progression of COVID-19 and symptomatically similar co-evolving influenza-like illnesses, as well as hospitalization and mortality rates. Designed to optimize healthcare deployment, which is especially important with hospitalizations resurging and healthcare workers increasingly becoming ill. (Alexander Rodriguez, Nikhil Muralidhar, Bijaya Adhikari, Naren Ramakrishnan, and B. Aditya Prakash - U.S.)
- Assessing Conservation Level of Therapeutic and Vaccine Targets of COVID-19. Predicts the effectiveness of vaccines and therapeutics by genome sequences and prioritizes relevant treatments to inform drug and vaccine development. (Yuanfang Guan and Manqi Zhou - U.S.)
Third-Place Awards - $12,500 each
- Analysis of COVID-19 Policies’ Impact on the Population and the Economy . Calculates the impact of government policies on COVID-19 infection rates, stock prices, and a population’s mobility to inform governments about how policies affect people and the economy. (Niti Wattanasirichaigoon, Napat Ratanakul, and Apiwat Jaroonpol - U.S., Singapore, and Japan)
- COVIDProf: An Intelligent Q&A Chatbot Tuned to Deliver Scientific Research and Data Related to COVID-19 in Natural Language. Makes finding and understanding relevant COVID-19 scientific research and data easier for the average person through an intelligent Q&A chatbot. (Varsha Rao and Joy Yeh - Singapore and Japan)
- Structural Modeling of COVID Spread in Relation to Human Mobility . Models causal relationships between human mobility indicators (trips, distance traveled, staying at home, and social distancing) and COVID-19 spread to inform how policymakers should take action. (Rezwana Rafiq, Tanjeeb Ahmed, and Md Yusuf Sarwar Uddin - U.S.)
- The Center on Stochastic Modeling, Optimization, and Statistics (COSMOS) COVID -19 Linear Programming. Online tool for reopening communities that enables decision makers to study hypothetical scenarios to inform planning and protect high-risk individuals. (Victoria Chen, Yuan Zhou, Nilabh Ohol, Alireza Fallahi, and Amith Viswanatha - U.S.)
Award Criteria
The projects were reviewed on the basis of their scientific merit, the use of AI, machine learning, and/or other data science techniques in the project, and the incorporation of at least two data sources from the C3 AI® COVID-19 Data Lake .
The evaluation process also considered the extent to which the derived data science insights, if implemented at scale, will result in significant public health and economic benefit.
To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/c3-ai-covid-19-grand-challenge/ .
About C3.ai
C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a proprietary, model-driven AI architecture that dramatically enhances data science and application development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
